A novel biomarker and therapeutic target for breast cancer
A novel biomarker and therapeutic target for breast cancer
批准号:
8220835
负责人:
M. SAEED SHEIKH
金额:
$17.35万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-02-15 至 2014-01-31
关键词:
AffectAntineoplastic AgentsApoptosisApoptoticBioinformaticsBiological MarkersBreast Cancer CellCell SurvivalCell physiologyCoupledCrista ampullarisDNA DamageDataDevelopmentERBB2 geneEarly DiagnosisFutureGrowthHealthHumanLesionLinkMalignant NeoplasmsMammary NeoplasmsMitochondriaMitochondrial CristaMitochondrial ProteinsMolecularMolecular ProfilingMolecular TargetMorphologyMusNoninfiltrating Intraductal CarcinomaNormal tissue morphologyOutcomeOutcome StudyPlayProteinsRegulationRoleSamplingSpecimenStagingStructureTestingTherapeuticXenograft Modelbasecohortin vivoinsightmRNA Expressionmalignant breast neoplasmmitochondrial dysfunctionnovelnovel markernovel therapeutic interventionoutcome forecastpre-clinicalpublic health relevanceresponsesmall moleculetherapeutic targettooltriple-negative invasive breast carcinomatumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Breast cancer is a major health problem here in the US and globally and thus, there is an urgent need to identify and develop novel markers for breast cancer that would facilitate early diagnosis and response to therapy and also serve as targets to develop novel therapeutic approaches. Mitochondria are involved in various cellular processes including control of apoptosis and mitochondrial dysfunction has also been associated with breast cancer. This application proposes to characterize a novel DNA damage-regulated mitochondrial anti-apoptotic protein CHCM1 (Coiled coil Helix Cristae Morphology 1) in human breast cancer. Our preliminary results indicate that CHCM1 expression is increased in human breast cancers and its knockdown sensitizes breast cancer cells to apoptosis induced by DNA damage inducing anticancer drugs. Our results also indicate that CHCM1 is linked to controlling mitochondrial cristae structures and that it interacts with mitofilin, which is another mitochondrial protein. Our hypothesis is that CHCM1 is a novel anti-apoptotic molecule that plays an important role in breast cancer cell survival and tumorigenesis. We also hypothesize that CHCM1 can potentially serve as a valuable novel marker for breast cancer and a molecular target to develop newer cancer therapeutic approaches. It is also our hypothesis that CHCM1 interacts with mitofilin to control the structural integrity of mitochondrial cristae and regulate cristae remodeling. We are proposing three specific aims to test these hypotheses. Specific aim 1 is to investigate CHCM1 expression in primary breast cancer samples and matching normal tissues. Specific aim 2 is to investigate the role of CHCM1 in in vivo breast cancer growth using a mouse xenograft model. Specific aim 3 involves structural functional characterization of CHCM1. The outcome of the proposed studies, if successful, will provide valuable information about the role of CHCM1 in breast cancer development and progression and facilitate the development of CHCM1 as a novel marker for breast cancer and a target for newer therapeutic approaches. The outcome will also provide valuable insights into the molecular mechanisms involved in regulation of mitochondrial cristae structure and remodeling particularly as they relate to pathobiology of breast cancer.
PUBLIC HEALTH RELEVANCE: The outcome of the proposed studies will provide valuable information about the role of CHCM1 in breast cancer development and progression and facilitate the development of CHCM1 as a novel marker for breast cancer and a target to develop newer therapeutic approaches. The outcome will also provide valuable insights into the molecular mechanisms involved in regulation of mitochondrial cristae structure and remodeling particularly as they relate to pathobiology of breast cancer.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
2013-12
期刊:
Molecular and cellular pharmacology
影响因子:
--
作者:
[M. Babbar;M. Sheikh]
通讯作者:
M. Babbar;M. Sheikh
Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.
Sacituzumab govitecan 用于治疗激素受体阳性和三阴性乳腺癌。
DOI:
--
发表时间:
2023
期刊:
Molecular and cellular pharmacology
影响因子:
--
作者:
[Satti,SiemA, Sheikh,MSaeed]
通讯作者:
Sheikh,MSaeed
RNA-binding Protein, GADD45-alpha, p27Kip1, p53 and Genotoxic Stress Response in Relation to Chemoresistance in Cancer.
RNA 结合蛋白、GADD45-α、p27Kip1、p53 和与癌症化疗耐药相关的基因毒性应激反应。
DOI:
--
发表时间:
2015
期刊:
Molecular and cellular pharmacology
影响因子:
--
作者:
[Sheikh,MSaeed]
通讯作者:
Sheikh,MSaeed
DOI:
--
发表时间:
2021
期刊:
Molecular and cellular pharmacology
影响因子:
--
作者:
[M. Sheikh;Siem A Satti]
通讯作者:
M. Sheikh;Siem A Satti
Development of dihydroartemisinin as a novel preventive agent for prostate cancer
-
批准号:8050362
-
项目类别:
-
资助金额:$7.96万
-
财政年份:2011
-
负责人:M. SAEED SHEIKH
-
依托单位:
Development of dihydroartemisinin as a novel preventive agent for prostate cancer
-
批准号:8242022
-
项目类别:
-
资助金额:$7.98万
-
财政年份:2011
-
负责人:M. SAEED SHEIKH
-
依托单位:
A novel biomarker and therapeutic target for breast cancer
-
批准号:8062885
-
项目类别:
-
资助金额:$20.73万
-
财政年份:2011
-
负责人:M. SAEED SHEIKH
-
依托单位:
Characterization of a novel stress-regulated anti-apoptotic ubiquitin ligase
-
批准号:7466107
-
项目类别:
-
资助金额:$23.55万
-
财政年份:2008
-
负责人:M. SAEED SHEIKH
-
依托单位:
Characterization of a novel stress-regulated anti-apoptotic ubiquitin ligase
-
批准号:7567486
-
项目类别:
-
资助金额:$19.63万
-
财政年份:2008
-
负责人:M. SAEED SHEIKH
-
依托单位:
PDRG, a novel p53 and DNA damage-regulated gene and colorectal cancer
-
批准号:7265025
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2007
-
负责人:M. SAEED SHEIKH
-
依托单位:
PDRG, a novel p53 and DNA damage-regulated gene and colorectal cancer
-
批准号:7426429
-
项目类别:
-
资助金额:$19.23万
-
财政年份:2007
-
负责人:M. SAEED SHEIKH
-
依托单位:
Characterization:novel genotoxic stress-regulated gene
-
批准号:7030099
-
项目类别:
-
资助金额:$22.8万
-
财政年份:2006
-
负责人:M. SAEED SHEIKH
-
依托单位:
Characterization:novel genotoxic stress-regulated gene
-
批准号:7229934
-
项目类别:
-
资助金额:$18.45万
-
财政年份:2006
-
负责人:M. SAEED SHEIKH
-
依托单位:
COX-2 and p53 interactions and cancer prevention
-
批准号:6804993
-
项目类别:
-
资助金额:$7.6万
-
财政年份:2003
-
负责人:M. SAEED SHEIKH
-
依托单位:
COX-2 and p53 interactions and cancer prevention
-
批准号:6728606
-
项目类别:
-
资助金额:$7.6万
-
财政年份:2003
-
负责人:M. SAEED SHEIKH
-
依托单位:
Characterization of a Novel Growth Regulator
-
批准号:6469960
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2002
-
负责人:M. SAEED SHEIKH
-
依托单位:
Characterization of a Novel Growth Regulator
-
批准号:7035761
-
项目类别:
-
资助金额:$24.68万
-
财政年份:2002
-
负责人:M. SAEED SHEIKH
-
依托单位:
Characterization of a Novel Growth Regulator
-
批准号:6731170
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2002
-
负责人:M. SAEED SHEIKH
-
依托单位:
Characterization of a Novel Growth Regulator
-
批准号:6623731
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2002
-
负责人:M. SAEED SHEIKH
-
依托单位:
Characterization of a Novel Growth Regulator
-
批准号:6878110
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2002
-
负责人:M. SAEED SHEIKH
-
依托单位:
Death receptors in prostate cancer biology and apoptosis
-
批准号:6514803
-
项目类别:
-
资助金额:$15.2万
-
财政年份:2001
-
负责人:M. SAEED SHEIKH
-
依托单位:
Death receptors in prostate cancer biology and apoptosis
-
批准号:6384220
-
项目类别:
-
资助金额:$15.2万
-
财政年份:2001
-
负责人:M. SAEED SHEIKH
-
依托单位:
海外基金